Literature DB >> 16912322

Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.

Nina R Derby1, Zane Kraft, Elaine Kan, Emma T Crooks, Susan W Barnett, Indresh K Srivastava, James M Binley, Leonidas Stamatatos.   

Abstract

The antibody responses elicited in rhesus macaques immunized with soluble human immunodeficiency virus (HIV) Env gp140 proteins derived from the R5-tropic HIV-1 SF162 virus were analyzed and compared to the broadly reactive neutralizing antibody responses elicited during chronic infection of a macaque with a simian/human immunodeficiency virus (SHIV) expressing the HIV-1 SF162 Env, SHIV(SF162P4), and humans infected with heterologous HIV-1 isolates. Four gp140 immunogens were evaluated: SF162gp140, DeltaV2gp140 (lacking the crown of the V2 loop), DeltaV3gp140 (lacking the crown of the V3 loop), and DeltaV2DeltaV3gp140 (lacking both the V2 and V3 loop crowns). SF162gp140 and DeltaV2gp140 have been previously evaluated by our group in a pilot study, but here, a more comprehensive analysis of their immunogenic properties was performed. All four gp140 immunogens elicited stronger anti-gp120 than anti-gp41 antibodies and potent homologous neutralizing antibodies (NAbs) that primarily targeted the first hypervariable region (V1 loop) of gp120, although SF162gp140 also elicited anti-V3 NAbs. Heterologous NAbs were elicited by SF162gp140 and DeltaV2gp140 but were weak in potency and narrow in specificity. No heterologous NAbs were elicited by DeltaV3gp140 or DeltaV2DeltaV3gp140. In contrast, the SHIV(SF162P4)-infected macaque and HIV-infected humans generated similar titers of anti-gp120 and anti-gp41 antibodies and NAbs of significant breadth against primary HIV-1 isolates, which did not target the V1 loop. The difference in V1 loop immunogenicity between soluble gp140 and virion-associated gp160 Env proteins derived from SF162 may be the basis for the observed difference in the breadth of neutralization in sera from the immunized and infected animals studied here.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16912322      PMCID: PMC1563892          DOI: 10.1128/JVI.00956-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  95 in total

1.  Interactions of human antibodies, epitope exposure, antibody binding and neutralization of primary isolate HIV-1 virions.

Authors:  Lisa A Cavacini; Mark Duval; James Robinson; Marshall R Posner
Journal:  AIDS       Date:  2002-12-06       Impact factor: 4.177

2.  Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies.

Authors:  Pascal Poignard; Maxime Moulard; Edwin Golez; Veronique Vivona; Michael Franti; Sara Venturini; Meng Wang; Paul W H I Parren; Dennis R Burton
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.

Authors:  Maxime Moulard; Sanjay K Phogat; Yuuei Shu; Aran F Labrijn; Xiaodong Xiao; James M Binley; Mei-Yun Zhang; Igor A Sidorov; Christopher C Broder; James Robinson; Paul W H I Parren; Dennis R Burton; Dimiter S Dimitrov
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

4.  Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design.

Authors:  Joseph G Joyce; William M Hurni; Michael J Bogusky; Victor M Garsky; Xiaoping Liang; Michael P Citron; Renee C Danzeisen; Michael D Miller; John W Shiver; Paul M Keller
Journal:  J Biol Chem       Date:  2002-09-16       Impact factor: 5.157

5.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

6.  The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

Authors:  Rogier W Sanders; Miro Venturi; Linnea Schiffner; Roopa Kalyanaraman; Hermann Katinger; Kenneth O Lloyd; Peter D Kwong; John P Moore
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

7.  Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci.

Authors:  Yuxian He; William J Honnen; Chavdar P Krachmarov; Michael Burkhart; Samuel C Kayman; Jose Corvalan; Abraham Pinter
Journal:  J Immunol       Date:  2002-07-01       Impact factor: 5.422

8.  Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein.

Authors:  Norbert Schülke; Mika S Vesanen; Rogier W Sanders; Ping Zhu; Min Lu; Deborah J Anselma; Anthony R Villa; Paul W H I Parren; James M Binley; Kenneth H Roux; Paul J Maddon; John P Moore; William C Olson
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

9.  Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface.

Authors:  Rob J Center; Richard D Leapman; Jacob Lebowitz; Larry O Arthur; Patricia L Earl; Bernard Moss
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

Authors:  Miroslaw K Gorny; Constance Williams; Barbara Volsky; Kathy Revesz; Sandra Cohen; Victoria R Polonis; William J Honnen; Samuel C Kayman; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

View more
  55 in total

1.  Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

Authors:  Michael Vaine; Shixia Wang; Anthony Hackett; James Arthos; Shan Lu
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

2.  Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.

Authors:  Nina R Derby; Sean Gray; Elizabeth Wayner; Dwayne Campogan; Giorgos Vlahogiannis; Zane Kraft; Susan W Barnett; Indresh K Srivastava; Leonidas Stamatatos
Journal:  Virology       Date:  2007-06-08       Impact factor: 3.616

3.  Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.

Authors:  David C Montefiori; Lynn Morris; Guido Ferrari; John R Mascola
Journal:  Curr Opin HIV AIDS       Date:  2007-05       Impact factor: 4.283

4.  Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses.

Authors:  Zane Kraft; Katharine Strouss; William F Sutton; Brad Cleveland; For Yue Tso; Patricia Polacino; Julie Overbaugh; Shiu-Lok Hu; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

5.  Improvement of antibody responses by HIV envelope DNA and protein co-immunization.

Authors:  Franco Pissani; Delphine C Malherbe; Jason T Schuman; Harlan Robins; Byung S Park; Shelly J Krebs; Susan W Barnett; Nancy L Haigwood
Journal:  Vaccine       Date:  2013-11-23       Impact factor: 3.641

6.  Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes.

Authors:  Catherine A Blish; D Noah Sather; George Sellhorn; Leonidas Stamatatos; Yide Sun; Indresh Srivastava; Susan W Barnett; Brad Cleveland; Julie Overbaugh; Shiu-lok Hu
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

7.  Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Authors:  James M Binley; Elizabeth A Lybarger; Emma T Crooks; Michael S Seaman; Elin Gray; Katie L Davis; Julie M Decker; Diane Wycuff; Linda Harris; Natalie Hawkins; Blake Wood; Cory Nathe; Douglas Richman; Georgia D Tomaras; Frederic Bibollet-Ruche; James E Robinson; Lynn Morris; George M Shaw; David C Montefiori; John R Mascola
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

8.  Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity.

Authors:  Hengyu Xu; Likai Song; Mikyung Kim; Margaret A Holmes; Zane Kraft; George Sellhorn; Ellis L Reinherz; Leonidas Stamatatos; Roland K Strong
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

9.  Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.

Authors:  D Noah Sather; Jakob Armann; Lance K Ching; Angeliki Mavrantoni; George Sellhorn; Zachary Caldwell; Xuesong Yu; Blake Wood; Steve Self; Spyros Kalams; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

10.  Differential pathogenicity of SHIV infection in pig-tailed and rhesus macaques.

Authors:  Patricia Polacino; Kay Larsen; Lindsey Galmin; John Suschak; Zane Kraft; Leonidas Stamatatos; David Anderson; Susan W Barnett; Ranajit Pal; Kristen Bost; A H Bandivdekar; Christopher J Miller; Shiu-Lok Hu
Journal:  J Med Primatol       Date:  2008-12       Impact factor: 0.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.